共 50 条
- [11] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)NEURO-ONCOLOGY, 2018, 20 : 230 - 230Lazaridis, L.Schaefer, N.Kebir, S.Weller, J.Tzaridis, T.Schaeffler, B.Pierscianek, D.Kleinschnitz, C.Stuschke, M.Sure, U.Herrlinger, U.Glas, M.
- [12] Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialLANCET, 2019, 393 (10172): : 678 - 688Herrlinger, UlrichTzaridis, TheophilosMack, FredericSteinbach, Joachim PeterSchlegel, UweSabel, MichaelHau, PeterKortmann, Rolf-DieterKrex, DietmarGrauer, OliverGoldbrunner, RolandSchnell, OliverBaehr, OliverUhl, MartinSeidel, ClemensTabatabai, GhazalehKowalski, ThomasRingel, FlorianSchmidt-Graf, FriederikeSuchorska, BogdanaBrehmer, StefanieWeyerbrock, AstridRenovanz, MiriamBullinger, LarsGalldiks, NorbertVajkoczy, PeterMisch, MartinVatter, HartmutStuplich, MoritzSchaefer, NiklasKebir, SiedWeller, JohannesSchaub, ChristinaStummer, WalterTonn, Joerg-ChristianSimon, MatthiasKeil, Vera C.Nelles, MichaelUrbach, HorstCoenen, MartinWick, WolfgangWeller, MichaelFimmers, RolfSchmid, MatthiasHattingen, ElkePietsch, TorstenCoch, ChristophGlas, Martin
- [13] Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialFRONTIERS IN ONCOLOGY, 2020, 10Das, SunitSahgal, ArjunPerry, James R.
- [14] Bevacizumab in Combination With Radiotherapy and Temozolomide for PatientsWith Newly Diagnosed Glioblastoma MultiformeONCOLOGIST, 2015, 20 (02): : 107 - 108van Linde, Myra E.Verhoeff, Joost J. C.Richel, Dirk J.van Furth, Bwouter R.Reijneveld, Jaap C.Verheul, Henk M. W.Stalpers, Lukas J. A.
- [15] FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF LOMUSTINE AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMANEURO-ONCOLOGY, 2022, 24Lazaridis, L.Schmidt, T.Agkatsev, S.Blau, T.Spille, D.Heider, S.Schulz, T.Bumes, E.Oster, C.Feldheim, J.Stummer, W.Kessler, A.Seidel, C.Hau, P.Sure, U.Keyvani, K.Herrlinger, U.Kleinschnitz, C.Stuschke, M.Herrmann, K.Deuschl, C.Hattingen, E.Scheffler, B.Kebir, S.Glas, M.
- [16] The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastomaJOURNAL OF NEURO-ONCOLOGY, 2013, 112 (02) : 277 - 283Park, Chul-KeeLee, Se-HoonKim, Tae MinChoi, Seung HongPark, Sung-HyeHeo, Dae SeogKim, Il HanJung, Hee-Won
- [17] The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastomaJournal of Neuro-Oncology, 2013, 112 : 277 - 283Chul-Kee ParkSe-Hoon LeeTae Min KimSeung Hong ChoiSung-Hye ParkDae Seog HeoIl Han KimHee-Won Jung
- [18] Radiosensitizers in the temozolomide era for newly diagnosed glioblastomaNEURO-ONCOLOGY PRACTICE, 2020, 7 (03) : 268 - 276Mathen, PeterRowe, LindsayMackey, MeganSmart, DeeDeeTofilon, PhilipCamphausen, Kevin
- [19] CHEMORADIOTHERAPY OF NEWLY DIAGNOSED GLIOBLASTOMA WITH INTENSIFIED TEMOZOLOMIDEINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (03): : 670 - 676Weiler, MarkusHartmann, ChristianWiewrodt, DorotheeHerrlinger, UlrichGorlia, ThierryBaehr, OliverMeyermann, RichardBamberg, MichaelTatagiba, Marcosvon Deimling, AndreasWeller, MichaelWick, Wolfgang
- [20] BEVACIZUMAB IN COMBINATION WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORMENEURO-ONCOLOGY, 2008, 10 (05) : 836 - 837Vredenburgh, JamesDesjardins, AnnickReardon, DavidRich, JeremyKirkpatrick, JohnGururangan, SridharanBailey, LeighannFriedman, AllanBigner, DarellFriedman, Henry